Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher – Tale of the Tape

Zacks

Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has now gained roughly 16% since Feb 21.

This biotechnology company has seen one negative estimate revision over the last 30 days and its Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Esperion Therapeutics has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the same industry include DepoMed Inc. (DEPO), Lannett Company, Inc. (LCI) and Shire plc (SHPG). All these stocks hold a Zacks Rank #1(Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply